SAN DIEGO, CA—Prior data from the SECURE-PCI study hinted that statin preloading might benefit patients with ACS undergoing PCI, but a new analysis suggests that the benefit might be particularly ...

AMSTERDAM, the Netherlands—For hemodynamically stable patients with STEMI and multivessel coronary artery disease, those who receive immediate complete revascularization fare just as well as those who ...

Boston, MA - Low-molecular-weight heparins (LMWHs) could potentially replace unfractionated heparin as the antithrombin of choice across the spectrum of acute coronary syndromes. In addition, they ...

Dual antiplatelet therapy (DAPT) consisting of aspirin plus a P2Y 12 inhibitor has been the standard of care to prevent thrombotic events in patients with acute coronary syndrome (ACS) undergoing ...

SAN DIEGO — In a secondary analysis from the SECURE-PCI trial, a periprocedural loading dose of atorvastatin reduced 30-day MACE rates in patients with STEMI undergoing PCI, researchers reported at ...

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com. Antiplatelet therapy with ticagrelor after primary PCI ...

Bivalirudin (Angiomax) prevailed for periprocedural anticoagulation during percutaneous coronary intervention (PCI) in acute myocardial infarction (MI), according to a patient-level meta-analysis.

PARSIPPANY, N.J. and INDIANAPOLIS, March 29, 2011 /PRNewswire/ -- Oral antiplatelet therapy Effient® (prasugrel) has been added to the updated clinical practice guidelines as a Class I recommended ...

MIAMI, Oct. 23, 2012 /PRNewswire/ -- Daiichi Sankyo, Inc. and Eli Lilly and Company (NYSE: LLY) today announced new results of two retrospective, observational, comparative effectiveness studies of ...

Premenopausal women presenting with acute coronary syndrome (ACS) are a unique and often underrecognized patient population. Although they are traditionally considered at lower cardiovascular risk ...

(HealthDay News) – There are no significant gender differences in outcomes between men and women undergoing percutaneous coronary intervention (PCI) with drug-eluting stent (DES) for the treatment of ...